ReviewNPJ vaccines2025
Synthetic biology-inspired development of live attenuated influenza vaccines.
Review in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- mRNA Vaccines for Influenza: Hope for a Universal Vaccine?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Attenuation of Influenza a Virus into Live Vaccines Through C-End Degrons.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lysosome-targeting live attenuated influenza vaccines elicit robust and broad immunity in mice.Nature communications · 2026Article
- Assessment of the Immunogenicity and Safety of an Inactivated Associated Vaccine Against Influenza and Newcastle Disease.Vaccines · 2026Article
- From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats.Frontiers in public health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Live attenuated influenza vaccines (LAIVs) provide robust, cross-protective immunity but have traditionally been developed empirically and are associated with safety concerns. Recent advances in rational design enable precise genetic modifications to enhance safety and immunogenicity. This review highlights key molecular strategies advancing next-generation LAIV development and their potential to accelerate the production of safer, more effective vaccines against seasonal and pandemic influenza.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.